Vivimed Labs
VIVIMEDLAB NSE
Vivimed Labs
HealthcareNSE: VIVIMEDLAB BSE: 532660 Pharmaceuticals & Biotechnology
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹50.00 Cr
Volatility
Moderate
P/E Ratio
-0.3
EBITDA
₹-152 Cr
Return on Equity
90.88%
Debt to Equity
0
Book Value
₹-29.98
52W High
₹29.4
52W Low
₹4.75
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
6- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -39.5% over past five years.
- Promoter holding is low: 7.57%
- Contingent liabilities of Rs.183 Cr.
- Company has high debtors of 236 days.
- Promoter holding has decreased over last 3 years: -13.4%
Growth Rate
Revenue Growth
-41.97% lower than
3Y
Net Income Growth
451% higher than
3Y
Cash Flow Change
92.71% higher than
3Y
ROE
-89.08% lower than
3Y
ROCE
-29.76% higher than
3Y
Quarterly Results
| Particulars | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 37 | 35 | 34 | 41 | 39 | 29 | 25 | 37 | 26 | 21 | 21 | 16 | 12 |
| Expenses | 201 | 36 | 40 | 40 | 67 | 40 | 25 | 35 | 28 | 22 | 22 | 27 | 152 |
| Operating Profit | -164 | 0 | -6 | 1 | -28 | -11 | -1 | 1 | -2 | 0 | -1 | -11 | -140 |
| OPM % | -444% | -0.9% | -18% | 3.1% | -74% | -37% | -2.6% | 2.9% | -10% | -1.3% | -4.6% | -68% | -1169% |
| Other Income | 1 | 0 | 2 | 0 | 8 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 6 |
| Interest | 9 | 11 | 12 | 13 | -33 | 0 | 0 | 0 | 2 | 1 | 2 | 1 | 1 |
| Depreciation | 96 | 5 | 5 | 5 | 6 | 4 | 4 | 7 | 6 | 5 | 5 | 5 | 12 |
| PBT | -268 | -16 | -20 | -17 | 7 | -15 | -5 | -6 | -5 | -5 | -7 | -17 | -147 |
| Tax % | -1% | 0% | 0% | -3% | 21% | 0% | 0% | 0% | 2% | 0% | 0% | 0% | 0% |
| Net Profit | -266 | -16 | -20 | -16 | 5 | -15 | -5 | -6 | -6 | -5 | -7 | -17 | -147 |
| EPS in Rs | -32.08 | -1.88 | -2.45 | -1.94 | 0.63 | -1.84 | -0.62 | -0.72 | -0.68 | -0.66 | -0.88 | -2 | -17.74 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,380 | 1,346 | 1,462 | 1,186 | 1,315 | 1,059 | 861 | 237 | 187 | 149 | 116 | 70 |
| Expenses | 1,156 | 1,111 | 1,057 | 971 | 1,135 | 1,049 | 830 | 245 | 374 | 182 | 129 | 222 |
| Operating Profit | 224 | 234 | 404 | 215 | 180 | 10 | 32 | -8 | -187 | -33 | -13 | -152 |
| OPM % | 16% | 17% | 28% | 18% | 14% | 1% | 3.7% | -3.3% | -100% | -22% | -11% | -218% |
| Other Income | 6 | 11 | 8 | 10 | 23 | 8 | 10 | 1 | 1 | 10 | 4 | 6 |
| Interest | 86 | 84 | 68 | 82 | 70 | 61 | 56 | 40 | 36 | 3 | 3 | 4 |
| Depreciation | 66 | 61 | 58 | 56 | 67 | 67 | 56 | 18 | 108 | 20 | 20 | 26 |
| PBT | 78 | 100 | 286 | 86 | 66 | -109 | -70 | -65 | -331 | -46 | -32 | -176 |
| Tax % | 7% | 16% | 25% | 11% | 13% | 0% | 3% | 4% | -1% | -1% | 0% | 0% |
| Net Profit | 72 | 84 | 214 | 76 | 57 | -109 | -72 | -68 | -329 | -45 | -32 | -176 |
| EPS in Rs | 8.9 | 10.33 | 26.41 | 9.44 | 6.95 | -13.16 | -8.67 | -8.16 | -39.62 | -5.48 | -3.85 | -21.28 |
| Div. Payout % | 0% | 0% | 2% | 4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 479 | 505 | 718 | 885 | 602 | 493 | 415 | 348 | 23 | -22 | -52 | -227 |
| Borrowings | 1,076 | 1,015 | 1,011 | 1,149 | 1,280 | 1,268 | 326 | 359 | 379 | 377 | 376 | 397 |
| Other Liabilities | 327 | 519 | 317 | 343 | 431 | 432 | 532 | 543 | 658 | 579 | 580 | 567 |
| Total Liabilities | 1,898 | 2,055 | 2,062 | 2,394 | 2,329 | 2,210 | 1,289 | 1,266 | 1,076 | 950 | 921 | 753 |
| Fixed Assets | 813 | 814 | 879 | 1,035 | 965 | 1,045 | 502 | 520 | 436 | 418 | 408 | 386 |
| CWIP | 90 | 94 | 76 | 65 | 122 | 89 | 60 | 40 | 21 | 21 | 17 | 18 |
| Investments | 3 | 3 | 3 | 3 | 3 | 86 | 199 | 199 | 199 | 168 | 168 | 181 |
| Other Assets | 992 | 1,144 | 1,104 | 1,290 | 1,239 | 990 | 529 | 507 | 421 | 343 | 328 | 170 |
| Total Assets | 1,898 | 2,055 | 2,062 | 2,394 | 2,329 | 2,210 | 1,289 | 1,266 | 1,076 | 950 | 921 | 753 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 140 | 154 | 58 | 21 | 422 | 80 | 567 | 28 | 35 | -24 | -2 | 8 |
| Investing | -107 | -190 | -68 | -164 | -89 | -196 | 404 | -16 | -5 | 28 | -5 | -1 |
| Financing | -42 | 41 | 35 | 186 | -338 | 72 | -1,015 | -10 | -34 | -6 | 5 | -6 |
| Net Cash Flow | -8 | 4 | 25 | 44 | -5 | -44 | -44 | 1 | -3 | -2 | -1 | 1 |
| Free Cash Flow | 16 | 95 | -11 | -142 | 333 | -33 | 1,084 | 11 | 30 | -26 | -6 | 7 |
| CFO/OP | 63 | 66 | 23 | 30 | 243 | 972 | 1,720 | -352 | -19 | 73 | 13 | -5 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 87 | 88 | 50 | 85 | 99 | 86 | 46 | 134 | 145 | 203 | 233 | 236 |
| Inventory Days | 244 | 294 | 329 | 411 | 397 | 396 | 263 | 573 | 216 | 327 | 358 | 63 |
| Days Payable | 107 | 98 | 122 | 154 | 207 | 179 | 35 | 100 | 74 | 225 | 240 | 263 |
| Cash Conversion Cycle | 224 | 285 | 258 | 342 | 288 | 303 | 274 | 607 | 286 | 305 | 351 | 36 |
| Working Capital Days | 43 | 58 | 55 | 121 | 68 | 216 | 77 | 195 | -15 | -171 | -255 | -1,468 |
| ROCE % | 11% | 12% | 22% | 9% | 7% | -3% | -1% | -3% | -52% | -11% | -8% | -65% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Vivimed Labs insights
55 extracted metrics + investor summaries across FY14–FY25.
Documents
1
Corporate Insolvency Resolution Process (CIRP)-Public Announcement
23 Apr - NCLT Bengaluru started CIRP for Vivimed Labs on 15.04.2026; claims due by 01.05.2026. 23 Apr - NCLT Bengaluru started CIRP for Vivimed Labs on 15.04.2026; claims due by 01.05.2026.
2
Corporate Insolvency Resolution Process (CIRP)-Public Announcement
14h - NCLT Bengaluru started CIRP for Vivimed Labs on 15.04.2026; claims due by 01.05.2026. 14h - NCLT Bengaluru started CIRP for Vivimed Labs on 15.04.2026; claims due by 01.05.2026.
3
Admission To CIRP
17 Apr - Vivimed Labs admitted to CIRP by NCLT Bengaluru; moratorium imposed and IRP appointed. 17 Apr - Vivimed Labs admitted to CIRP by NCLT Bengaluru; moratorium imposed and IRP appointed.
4
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Submitted Regulation 74(5) compliance certificate for quarter ended 31 March 2026. 8 Apr - Submitted Regulation 74(5) compliance certificate for quarter ended 31 March 2026.
5
Initial Disclosure
6 Apr - Vivimed Labs declares it is outside the SEBI large corporate entity framework. 6 Apr - Vivimed Labs declares it is outside the SEBI large corporate entity framework.
1
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors 8 Sept 2026
General_Announcements
2
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors 17 Aug 2026
General_Announcements
Frequently Asked Questions about Vivimed Labs
What does Vivimed Labs Ltd do?
Vivimed Labs Ltd, established in 1988, is primarily engaged in the Business of Active Pharmaceuticals Ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals and Retail Branded Formulation manufacturing.[1][2]
Where is Vivimed Labs Ltd (VIVIMEDLAB) listed?
Vivimed Labs Ltd trades as VIVIMEDLAB on the NSE and under code 532660 on the BSE.
Which sector does Vivimed Labs Ltd belong to?
Vivimed Labs Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Vivimed Labs Ltd?
Vivimed Labs Ltd has a market capitalisation of ₹50 Cr, which places it in the Small Cap band.
What is the PE ratio of Vivimed Labs Ltd?
Vivimed Labs Ltd trades at a PE ratio of -0.30, against a book value of ₹-29.98 per share.
What is the 52-week high and low of Vivimed Labs Ltd?
Over the last 52 weeks Vivimed Labs Ltd has traded between ₹4.75 and ₹29.4.
What is the Return on Equity (ROE) of Vivimed Labs Ltd?
Vivimed Labs Ltd reported a return on equity of 90.88%. Its debt-to-equity ratio is 0.00.
Company Information
Vivimed Labs Ltd, established in 1988, is primarily engaged in the Business of Active Pharmaceuticals Ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals and Retail Branded Formulation manufacturing.[1][2]
Website vivimedlabs.com
CEO Dr. Manohar Rao Varalwar
Employees 586
Listed 2005-08-17
Face Value ₹ 2
Issued Size 8,29,13,915
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/VIVIMEDLAB.md for Vivimed Labs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.